Republicans Eye Taxes on Employer Health Plans
Senate Republicans working on a healthcare bill are considering raising billions of dollars in revenue through a tax on employer-sponsored insurance plans. According to The Wall Street Journal, under current law health insurance is tax exempt and previous attempts to change the law have failed. The proposal is likely to face strong resistance, as in the past, and could raise taxes on millions of people.
Global Cost of Cancer Treatment
In the last 5 years, the global cost of cancer treatments has grown annually by 8.7%. However, the rising cost of treating cancer isn’t just about rising drug prices, according to Fierce Pharma. New oncology treatments bring better outcomes, which means patients taking them are living longer and staying on therapy longer. Two-thirds of the growth in cancer costs can be attributed to new drugs that have improved survival. The United States accounts for 46% of the world’s oncology costs.
After Surviving an Opioid Overdose
The majority of people who survive an opioid overdose go back to using the drugs, so some states are sending recovery coaches to the hospital to meet overdose survivors, reported The Pew Charitable Trusts. Recovery coaches inform overdose survivors of the resources available to help them quit and how they can reduce the risk of another overdose if they keep using. In some states, they might distribute naloxone kits and train survivors and friends and family on how to use them.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients
January 13th 2025Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers
January 2nd 2025Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.
Read More